TY  - JOUR
AU  - Naranjo, Javier
AU  - Borrego, Francisco
AU  - Rocha, Jose Luis
AU  - Salgueira, Mercedes
AU  - Martin-Gomez, Maria Adoracion
AU  - Orellana, Cristhian
AU  - Morales, Ana
AU  - Vallejo, Fernando
AU  - Hidalgo, Pilar
AU  - Rodriguez, Francisca
AU  - Garofano, Remedios
AU  - Gonzalez, Isabel
AU  - Esteban, Rafael
AU  - Espinosa, Mario
PY  - 2022
DO  - 10.3389/fmed.2022.987092
SN  - 2296-858X
UR  - http://hdl.handle.net/10668/20610
T2  - Frontiers in medicine
AB  - Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatment. A...
LA  - en
PB  - Frontiers Research Foundation
KW  - glomerular filtration rate (eGFR)
KW  - hepatic toxicity
KW  - polycystic kidney disease (PKD)
KW  - tolvaptan
KW  - urinary osmolality
KW  - Humans
KW  - Tolvaptan
KW  - Antidiuretic Hormone Receptor Antagonists
KW  - Polycystic Kidney, Autosomal Dominant
KW  - Prospective Studies
KW  - Antihypertensive Agents
KW  - Blood Pressure
KW  - Uric Acid
KW  - Glomerular Filtration Rate
KW  - Hepatitis
KW  - Osmolar Concentration
KW  - Vasopressins
KW  - Sodium
TI  - Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease.
TY  - research article
VL  - 9
ER  -